Apellis Pharmaceuticals Inc

NASDAQ:APLSUnited States

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Contact Information

Headquarters

100 Fifth AvenueWALTHAM, MA, United States 02451

Phone

617-977-5700

Fax

916-443-1908

Executives

Independent Chairman of the Board

Gerald Chan

President, Chief Executive Officer, Co-Founder, Director

Cedric Francois

Co-Founder, Chief Scientific Officer

Pascal Deschatelets

Chief Financial Officer, Treasurer

Timothy Sullivan

Chief Technical Operations Officer

Nur Nicholson